HomeHealthcare & Life Sciences Benign Prostatic Hyperplasia Treatment Market

Global Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological treatmentAlpha-blockersTamsulosinSilodosinAlfuzosinDoxazosinOther alpha-blockers5-alpha reductase inhibitors (5-ARI)DutasterideFinasterideCombination therapyAlpha-blockers + 5-arisAlpha-blockers + pde5 inhibitorsPhosphodiesterase-5 inhibitors (pde5 inhibitors)Herbal and other drugs, Surgical treatmentTransurethral resection of the prostate (TURP)Transurethral incision of t

Starting From
USD 3950

Buy Now

Report Benefits

Develop business strategies by understanding the trends shaping and driving the Market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track sales in the global and country-specific Market.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Benign Prostatic Hyperplasia Treatment Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Benign Prostatic Hyperplasia Treatment Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Benign Prostatic Hyperplasia Treatment Market, By Treatment Type
1. Introduction
  1. Market Size and Forecast, By Treatment Type
2. Pharmacological treatment
  1. Market Size and Forecast, By Region
  2. Alpha-blockers
    1. Market Size and Forecast, By Region
    2. Tamsulosin
      1. Market Size and Forecast, By Region
    3. Silodosin
      1. Market Size and Forecast, By Region
    4. Alfuzosin
      1. Market Size and Forecast, By Region
    5. Doxazosin
      1. Market Size and Forecast, By Region
    6. Other alpha-blockers
      1. Market Size and Forecast, By Region
  3. 5-alpha reductase inhibitors (5-ARI)
    1. Market Size and Forecast, By Region
    2. Dutasteride
      1. Market Size and Forecast, By Region
    3. Finasteride
      1. Market Size and Forecast, By Region
  4. Combination therapy
    1. Market Size and Forecast, By Region
    2. Alpha-blockers + 5-aris
      1. Market Size and Forecast, By Region
    3. Alpha-blockers + pde5 inhibitors
      1. Market Size and Forecast, By Region
  5. Phosphodiesterase-5 inhibitors (pde5 inhibitors)
    1. Market Size and Forecast, By Region
  6. Herbal and other drugs
    1. Market Size and Forecast, By Region
3. Surgical treatment
  1. Market Size and Forecast, By Region
  2. Transurethral resection of the prostate (TURP)
    1. Market Size and Forecast, By Region
  3. Transurethral incision of the prostate (TUIP)
    1. Market Size and Forecast, By Region
  4. Open prostatectomy
    1. Market Size and Forecast, By Region
  5. Laser therapy
    1. Market Size and Forecast, By Region
    2. Holmium laser enucleation of the prostate (HOLEP)
      1. Market Size and Forecast, By Region
    3. Photoselective vaporisation of the prostate (PVP)
      1. Market Size and Forecast, By Region
4. Minimally invasive procedures
  1. Market Size and Forecast, By Region
  2. Urolift system
    1. Market Size and Forecast, By Region
  3. RezÅ«m water vapour therapy
    1. Market Size and Forecast, By Region
  4. Prostatic artery embolisation
    1. Market Size and Forecast, By Region
  5. Microwave thermotherapy
    1. Market Size and Forecast, By Region
  6. Transurethral needle ablation (TUNA)
    1. Market Size and Forecast, By Region
5. Other treatments
  1. Market Size and Forecast, By Region
  2. Lifestyle modifications
    1. Market Size and Forecast, By Region
  3. Watchful waiting / active surveillance
    1. Market Size and Forecast, By Region
Benign Prostatic Hyperplasia Treatment Market, By End Use
1. Introduction
  1. Market Size and Forecast, By End Use
2. Hospitals
  1. Market Size and Forecast, By Region
3. Clinics
  1. Market Size and Forecast, By Region
4. Ambulatory surgical centres
  1. Market Size and Forecast, By Region
5. Specialty urology centers
  1. Market Size and Forecast, By Region
Benign Prostatic Hyperplasia Treatment Market, By Patient Age Group
1. Introduction
  1. Market Size and Forecast, By Patient Age Group
2. Below 50 years
  1. Market Size and Forecast, By Region
3. 50–60 years
  1. Market Size and Forecast, By Region
4. Above 60 years
  1. Market Size and Forecast, By Region
Benign Prostatic Hyperplasia Treatment Market, By Distribution Channel
1. Introduction
  1. Market Size and Forecast, By Distribution Channel
2. Hospital pharmacy
  1. Market Size and Forecast, By Region
3. Retail pharmacy
  1. Market Size and Forecast, By Region
4. Online pharmacy
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  2. U.S.
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  2. U.K.
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  2. China
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  3. South Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  2. UAE
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  2. Brazil
    1. By Treatment Type
      1. Pharmacological treatment
      2. Surgical treatment
      3. Minimally invasive procedures
      4. Other treatments
    2. By End Use
      1. Hospitals
      2. Clinics
      3. Ambulatory surgical centres
      4. Specialty urology centers
    3. By Patient Age Group
      1. Below 50 years
      2. 50–60 years
      3. Above 60 years
    4. By Distribution Channel
      1. Hospital pharmacy
      2. Retail pharmacy
      3. Online pharmacy
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2025
1. Introduction
2. Benign Prostatic Hyperplasia Treatment Market Share Analysis, 2025 (%)
  1. Market Share Analysis, 2025
  2. Competition Ranking, 2025
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. Boston Scientific Corporation
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Teleflex Incorporated
3. Olympus Corporation
4. KARL STORZ
5. PROCEPT BioRobotics
6. GlaxoSmithKline
7. Astellas Pharma
8. Viatris
9. Teva Pharmaceutical Industries
10. Sanofi
11. Bayer
12. Eli Lilly and Company
13. Proverum
14. Zenflow

Report Benefits

Table of Contents